Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UCB Seeks FDA Approval For Cimzia In Rheumatoid Arthritis

This article was originally published in The Pink Sheet Daily

Executive Summary

The biologic, which has yet to obtain a Crohn’s indication in the U.S. and Europe, is backed by efficacy data from three Phase III trials in RA.

You may also be interested in...



Cimzia Rheumatoid Arthritis Approval Held Up By Safety Request

UCB receives “complete response” letter from FDA on second indication for the biologic, approved for Crohn’s disease with a REMS.

Cimzia Rheumatoid Arthritis Approval Held Up By Safety Request

UCB receives “complete response” letter from FDA on second indication for the biologic, approved for Crohn’s disease with a REMS.

J&J/Centocor Files Golimumab In Three Indications

Company seeks approval in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.

Related Content

Topics

UsernamePublicRestriction

Register

OM001644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel